NLTX - Neoleukin files U.S. trial application for early-stage solid tumor study with its lead protein immunotherapy Candidate

Neoleukin Therapeutics ([[NLTX]] +0.4%) has submitted an Investigational New Drug ((IND)) application with the FDA to initiate a Phase 1 study its lead immunotherapeutic candidate, NL-201. NL-201 is a computationally designed de novo protein that is a mimetic of natural cytokines IL-2 and IL-15.The trial with 120 relapsed or refractory solid tumors patients will assess safety, pharmacokinetics, pharmacodynamics, and antitumor activity.

For further details see:

Neoleukin files U.S. trial application for early-stage solid tumor study with its lead protein immunotherapy Candidate